US FDA gives guidance on risk presentation in DTC ads
This article was originally published in Scrip
Executive Summary
Pharmaceutical manufacturers should present a comparable quantity of benefit and risk information in product advertisements and avoid using distracting graphics that detract from a reasonable consumer's comprehension of the risk presentation, the US FDA said in new draft guidelines.